FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:955-956 March 25, 1999 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kearon, C. PubMed Citation

The lethal complication of deep-vein thrombosis is pulmonary embolism. Since about 80 percent of the patients who die of pulmonary embolism succumb within two hours of the onset of symptoms,¹ intervention must focus on prevention. Patients who have had a thromboembolic event are at increased risk for recurrence. Oral anticoagulant therapy has up to 90 percent efficacy in preventing repeated episodes. Although the optimal intensity of anticoagulation with warfarin in this situation has been determined,² generally with an international normalized ratio (INR) of 2.0 to 3.0 set as the target, the optimal duration of prophylaxis has remained uncertain since the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Blackshear, J. L. (2004). Closure of patent foramen ovale in cryptogenic stroke: Ready or not, here come the trials. J Am Coll Cardiol 44: 759-761 [Full Text]  
• Rascona, D. A. (2004). Prevention of Fatal Pulmonary Embolism in the Hospital. Chest 125: 1595-1596 [Full Text]  
• Schafer, A. I., Levine, M. N., Konkle, B. A., Kearon, C. (2003). Thrombotic Disorders: Diagnosis and Treatment. ASH Education Book 2003: 520-539 [Abstract] [Full Text]  
• Agnelli, G., Prandoni, P., Santamaria, M. G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., Scannapieco, G., Ascani, A., Villalta, S., Frulla, M., Mosena, L., Girolami, A., Vaccarino, A., Alatri, A., Palareti, G., Marchesi, M., Ambrosio, G. B., Parisi, R., Doria, S., Steidl, L., Ambrosini, F., Silingardi, M., Ghirarduzzi, A., Iori, I., Ageno, W., the Warfarin Optimal Duration Italian Trial Invest, (2001). Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. NEJM 345: 165-169 [Abstract] [Full Text]  
• Beyth, R. J (2000). The recurrence rate of venous thromboembolism after a first or second episode of deep venous thrombosis was high. Evid. Based Med. 5: 188-188 [Full Text]  
• Baglin, T. (2000). Thrombophilia testing: what do we think the tests mean and what should we do with the results?. J. Clin. Pathol. 53: 167-170 [Full Text]  
• Horne III, M. K., Chang, R. (1999). Thrombolytic Therapy for Deep Venous Thrombosis?. JAMA 282: 2164-2166 [Abstract] [Full Text]  
• Lodwick, A. (1999). State-of-the-Art Review: Warfarin Therapy: A Review of the Literature Since the Fifth American College of Chest Physicians' Consensus Conference on Antithrombotic Therapy. CLIN APPL THROMB HEMOST 5: 208-215